Background: Therapeutic plasma exchange (TPE) is used increasingly in small animals to
| INTRODUCTION
Therapeutic plasma exchange (TPE) is an extracorporeal blood purification technique aiming at removing large molecular weight compounds from the circulation. 1 Main indications include immune-mediated diseases, hyperviscosity syndrome and toxicosis caused by highly protein-bound solutes. 2 Aside from the older manual centrifugation, 2 main modern techniques have been developed to separate the plasma from the blood circulating in an extracorporeal circuit: continuous flow centrifugation-based TPE (cTPE) and membrane filtration TPE (mTPE). 1, 3 Although the cTPE platforms offer the possibility of other apheresis techniques such as red cell, white cell, or platelet apheresis, they require specific machines that are only available in few specialized institutions. The technique of mTPE, however, has become more widely available, with the development of multifunctional blood purification platforms, allowing a wide spectrum of organ replacement treatments including renal, liver, or pulmonary support. Safe extracorporeal treatments require a good understanding of the physiological, hematological, and biochemical changes expected from the treatments.
Although most treatments are initially inspired by human protocols, extrapolation to dogs and cats with their diseases and their specific pathophysiological, cardiovascular, and metabolic responses has limitations. Small animal protocols therefore need to be established based on species-specific data, but few cases have been published, reporting its use in toxicoses, [4] [5] [6] hyperviscosity syndromes, [7] [8] [9] [10] [11] immune-mediated diseases, [12] [13] [14] [15] [16] [17] and microangiopathy. 18 The mTPE technique uses a continuous extracorporeal circulation and a hollow-fiber plasma separator with a large pore high cutoff membrane retaining only the cellular blood elements and filtering out the plasma. Replacement fluids are used for isovolemic reconstitution of the blood and for compensation of the discarded plasma components. Fresh-frozen plasma (FFP) typically is the first-choice replacement, but most TPE indications do not require 100% FFP and some of the plasma can be replaced by albumin, colloids, or crystalloids, depending on the underlying disease.
For animals at risk of bleeding, systemic heparinization (SH) can be replaced by regional citrate anticoagulation (RCA) for extracorporeal blood purification techniques. 19 However, the clearance of solutes in mTPE being limited by a maximal filtration fraction of 20%-25%, citrate and citrate-calcium complexes tend to accumulate when their administration rate exceeds the capacity of hepatic metabolism. The resulting citrate toxicosis can lead to ionized hypocalcemia, total hypercalcemia, and metabolic alkalosis, limiting the blood flow rate and the substitution rate with citrate-containing FFP. Therefore, RCA is considered relatively contraindicated for mTPE in humans. 20, 21 For diseases with hemostatic disorders including thrombocytopenia, disseminated intravascular coagulation, pulmonary hemorrhages, or central nervous system bleeding, SH remains an absolute contraindication and RCA has been used tentatively at low administration rates. Data on citrate tolerance in TPE treatments for dogs are therefore needed to improve the safety of the procedure and to widen the spectrum of treatable conditions.
The aims of this retrospective study were therefore to describe the technique of mTPE as used in our hospital and to analyze the clinical and clinicopathological changes associated with the treatment. The tolerance to citrate administration during mTPE was analyzed to define a tentative and potentially safe administration rate for dogs.
| MATERIALS AND METHODS

| Study design and animals
This study was designed as a retrospective evaluation of data collected from treatments based on prospectively planned protocols. Dogs treated with mTPE between 2011 and 2017 were included in the analysis. Their medical and treatment records were analyzed and following data were extracted: signalment, disease and indication for mTPE treatment, vascular access, treatment prescription, clinicopathological data before and after treatment, and specifics of anticoagulation.
| Specifics of mTPE treatment
Vascular access was provided using a right jugular central venous catheter adapted to the size of the dog and dedicated strictly to the blood purification procedure. Between the individual treatments, the access catheter was locked either with sodium citrate (46.7%, DuraLock c , Medcomp, Euromed Swiss AG, Frauenfeld, Switzerland) or with unfractionated heparin (50-1000 IU/mL, Heparin Bichsel, Dr G. Bichsel Pharmacy, Interlaken, Switzerland).
The mTPE treatment was performed on a Prismaflex platform, using a TPE 1000 circuit (Baxter Healthcare, Glattpark, Switzerland).
This pre-connected set has a total priming blood volume of 71 mL.
The incorporated plasmafilter with a polypropylene membrane has a blood volume of 23 mL and an effective filtration surface area of 0.15 m 2 . Its sieving coefficient for albumin is 0.97, for IgG 1.00, and for IgM 0.92 (manufacturer's data). Treatments were prescribed based on human protocols and were adjusted individually depending on the actual requirements of the animals, the perceived complication risks, and the response to previous treatments. The basis for the calculation of the mTPE prescription was to provide 10%-30% HAlb, 0%-10% HES, and 0%-50% saline, administered sequentially; it was adjusted to the individual needs of the animals, taking in consideration the underlying disease and comorbid disorders, the cardiovascular condition, and the hemostatic status. 3 | RESULTS
| Animals and diseases
Thirty-four dogs were treated with mTPE, including 19 males (12 intact, 35%; 7 castrated, 21%) and 15 females (5 intact, 15%; 10 spayed, 29%).
Thirty-two dogs were pure-bred dogs from 26 different breeds, and immune-mediated thrombocytopenia, n = 9; leptospirosis-associated pulmonary hemorrhages, n = 13; and neuromuscular diseases, n = 2).
Other indications included polysystemic diseases in 5 dogs (sepsis, n = 4; microangiopathy, n = 2), and hyperviscosity in 3 dogs (leishmaniasis, n = 3). More than 1 indication was present in 7 dogs.
| Specifics of the mTPE treatments
Sixty-four mTPE treatments were performed with a median of 2 treatments per dog (range, 1-3). Vascular access was provided with double-lumen central venous or hemodialysis catheters with diameters (7-13.5 Fr) and lengths (16-28 cm) adapted to the dog's size. P < .001), whereas serum albumin did not change significantly with a reduction ratio of 5.1% (IQR, −10.8 to 12.5, P = .13). The azotemia decreased significantly but only minimally with a median urea reduction ratio of 9.0% (IQR, 0.7-15.7; P < .001) and a creatinine reduction ratio of 4.5% (IQR, −6.6 to 10.6; P = .006). For dogs with markedly increased serum bilirubin pretreatment (>2.9 mg/dL, 50 μmol/L, n = 11), the total bilirubin concentration decreased significantly with a median reduction ratio of 36% (IQR, 13%-43%, P = .02). The only significant change noted in the coagulation profile was a marked decrease in fibrinogen concentration by 53% (IQR, −30 to 63; P = .009), without relevant changes in the coagulation times. Only minimal changes were noted in the acid-base variables, including significant but non clinically relevant metabolic acidosis and acidemia (Table 3) .
| Treatment complications
Complications were observed in 22/64 treatments (34%). One technical complication because of low blood flow rates in a small-sized dog caused early discontinuation of the treatment, but all other treatments could be performed to satisfaction and reached >90% of the plasma exchange goal. The following complications were observed: vomiting or at rechecks after their discharge from hospital (n = 16).
| Anticoagulation and citrate toxicosis
Three anticoagulation strategies were used in the mTPE treatments:
SH for 2 treatments (3%), RCA for 24 treatments (38%), and HepCit for 38 treatments (59% Abbreviations: AG, anion gap; BE, base excess; FFP, fresh-frozen plasma; HAlb, human albumin; HES, hydroxyethylstarch; mTPE, membrane-based therapeutic plasma exchange; NaCl, saline; RR, reference range. *P < .001, for paired comparison between pre-and post-mTPE with a Wilcoxon signed-rank test. The dogs showed evidence suggestive of citrate accumulation in all treatments, with a decrease in iCa, an increase in niCa, an increase in TCa, and an increase in the TCa:iCa ratio (Table 4 and Figure 1 ). Interestingly, although citrate is metabolized primarily in the liver, even severe liver function impairment was not associated with an increased risk of citrate accumulation. Similar total citrate loads between dogs with and without liver failure suggest that this was not F I G U R E 1 Changes in A, ionized calcium; B, non-ionized calcium; C, total calcium; and D, total calcium to ionized calcium ratio with membrane-based therapeutic plasma exchange (mTPE). The histograms represent the data before (green) and after (blue) mTPE treatment, as well as their resulting changes (red). Widths of the categories are 0.1 mmol/L for iCa, 0.25 mmol/L for niCA, and 0.5 mmol/L for TCa and TCa:iCa. iCa, ionized calcium; niCa, non-ionized calcium; TCa, total calcium; TCa:iCa, total calcium to ionized calcium ratio because of a particularly restrictive citrate administration or FFP transfusion rates in the affected dogs. In a multicenter prospective study looking at the safety of RCA in intensive human patients with various degrees of liver failure, a sufficient cellular respiration was suspected to be essential for the liver metabolism of citrate rather than the degree of liver function per se. 25 Various types of liver diseases may therefore affect the capacity of hepatic citrate metabolism differently.
T A B L E 2 Changes in laboratory variables associated with mTPE treatment
Although one third of the treatments were associated with complications, most of those were mild and self-limiting, and only 1 treatment had to be discontinued early, not reaching its exchange target.
In that and 4 other treatments in very small-sized dogs, the required minimal blood flow rate of 50 mL/min was not reached consistently, causing difficulties with the mandatory auto-test of the machine, emphasizing the need for a reliable large-bore venous access. Although most cTPE platforms have larger extracorporeal circuit volumes than mTPE platforms, they can function effectively with inlet blood flow rates as low as 5 mL/min, which can be very helpful for small animals.
The allergic-type reactions with chemosis, urticaria, and laryngeal edema observed in 3 dogs responded quickly to antihistamines and steroids.
Nevertheless, we decided to change our protocol and not to rely solely with 100% FFP is also rare and it is reserved for specific conditions. respectively. Neither hospital-acquired AKI nor progressive proteinuria could be detected in these dogs during hospitalization or follow-up.
However, as not all dogs could be monitored for at least 14 days following administration of HAlb and HES, caution is warranted until the safety of these solutions is better characterized in animals and a systematic long-term follow-up should be implemented in dogs receiving these solutions for this or other indications. In the meantime, we decided to minimize the use of these solutions. 
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